GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial
Cubala, W.J. et al. • 2026 • JAMA Psychiatry
FindingPhase 2b randomized controlled trial: a single-day inhaled mebufotenin (5-MeO-DMT) protocol produced 57.5% remission at day 8 versus 0% on placebo in treatment-resistant depression.
View on PubMed(opens in a new tab)
